Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy
- 15 April 1981
- Vol. 47 (8) , 1959-1962
- https://doi.org/10.1002/1097-0142(19810415)47:8<1959::aid-cncr2820470808>3.0.co;2-x
Abstract
ICRF‐187 (NSC‐169780), the (+) enantiomer of the racemic antineoplastic agent ICRF‐159 (NSC‐129943), was administered intravenously for five days every three weeks to 18 patients in a phase I study. Leukopenia was the dose‐limiting toxicity. Mild reversible elevations in SGOT and bilirubin were common. Other toxicities were mild and infrequent. Recommended doses of ICRF‐187 for phase II studies are 800 mg/m2for heavily pretreated patients and 1250 mg/m2for patients with little or no prior therapy. A daily five day intravenous schedule should be used. Other potential clinical uses of ICRF‐187 are discussed.This publication has 9 references indexed in Scilit:
- A clinical evaluation of ICRF 159 as a radiosensitising agentInternational Journal of Radiation Oncology*Biology*Physics, 1978
- PHASE-II STUDY OF ICRF-159 IN NON-HODGKINS LYMPHOMAS1978
- ICRF-159: Current status and clinical prospectsPublished by Elsevier ,1977
- Utilization of an enantiomer as a solution to a pharmaceutical problem: Application to solubilization of 1,2‐di(4‐piperazine‐2,6‐dione)propaneJournal of Pharmaceutical Sciences, 1976
- Metastases and the Normalization of Tumour Blood Vessels by ICRF 159: A New Type of Drug ActionBMJ, 1972
- Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant CharacteristicBMJ, 1970
- Antitumour Activity in a Series of bisDiketopiperazinesNature, 1969
- Preliminary Clinical Assessment of I.C.R.F. 159 in Acute Leukaemia and LymphosarcomaBMJ, 1969